Beyond Air (XAIR) Q3 2026 Earnings Call Highlights
Beyond Air (XAIR) delivered impressive results in its Q3 2026 earnings call, showcasing significant growth and strategic advancements.
Revenue Growth
The company announced a remarkable 105% year-over-year increase in revenue, reaching $2.2 million for the fiscal quarter ending December 31, 2025.
Gross Profit Improvement
Gross profit for the fiscal third quarter was reported at $300,000, a turnaround from a gross loss of $200,000 in the same period last year.
Operating Expenses Reduction
Beyond Air effectively managed its costs, reducing operating expenses to approximately $6.9 million, down from $10.7 million, marking a 36% reduction year-over-year.
Research and Development
Research and development expenses were reported at $2.4 million, down from $3 million during the same quarter last year.
SG&A Expenses
Sales, General and Administrative (SG&A) expenses also saw a decrease, totaling $4.5 million for the quarter, down from $7.7 million, representing a 42% year-over-year drop.
Net Loss
Despite the positive revenue growth, the net loss attributed to common stockholders was $7.3 million, translating to a loss of $0.85 per share, compared to $13 million or a loss of $2.96 per share in the previous year.
Cash Position
As of December 31, 2025, Beyond Air reported $17.8 million in cash and equivalents, with a net cash burn of $4.3 million for the quarter, reflecting a reduction of over 40% compared to the previous year.
Positive Highlights
- Customer retention rates exceed 90%, with many clients under multiyear agreements.
- The global distribution network for the LungFit PH has expanded to 40 countries.
- The company successfully completed a $5 million financing round.
Challenges Ahead
- The lengthy sales cycle of 6 to 9 months could delay revenue recognition.
- Awaiting FDA approval for the second-generation system remains a significant hurdle.
- There is uncertainty regarding the efficacy of the NeuroNOS platform in human trials.
Q & A Highlights
During the Q&A session, Interim Chief Commercial Officer Robert Goodman addressed strategies for penetrating healthcare systems, emphasizing the ECAD system's role in simplifying access.
Goodman also noted improvements in targeting facilities most likely to acquire the LungFit PH system through enhanced CRM tools.
CEO Steven Lisi provided updates on the FDA approval process for the Gen II system, indicating positive communication and no anticipated hurdles, while also discussing international expansion successes.
For more insights into the financial performance and strategic direction of Beyond Air, visit Inside Ticker.